眼科

订阅

MedSci主页 / 所有栏目 / 眼科

IEEE Trans Biomed Eng：从D-OCT图像突出显示视网膜结构的定向反射特性

2019-02-28 不详 网络

D-OCT图像视网膜结构定向反射特性
关注

近日，Rossant F和Grieve K等人在IEEE Trans Biomed Eng杂志上发表了一篇文章，作者提出了一种先进的图像处理方法，来执行一组D-OCT图像的差异分析，并提取角度依赖的视网膜子结构。

近日，Rossant F和Grieve K等人在IEEE Trans Biomed Eng杂志上发表了一篇文章，作者提出了一种先进的图像处理方法，来执行一组D-OCT图像的差异分析，并提取角度依赖的视网膜子结构。

光学相干断层扫描（OCT）能够实现视网膜的横向光学成像，并因此识别不同的神经元层。定向OCT（D-OCT）通过在光束的不同入射角处获取多组图像来对该技术进行了扩展。通过这种方式，可以突出显示感光器子结构的反射特性，使医生能够研究它们的方向，这可能是视网膜疾病的一个生物标志物。然而，配备用于自动化D-OCT采集的商用OCT设备尚不存在，这意味着医生需要手动移动光束，来连续的地获取一组D-OCT图像。因此，图像堆叠中的强度不能直接进行比较，并且在差分分析之前需要归一化处理。

在本文中，作者提出了一种先进的图像处理方法，来执行一组D-OCT图像的差异分析，并提取角度依赖的视网膜子结构。他我们的方法依赖于稳健且准确的归一化算法，然后是空间正则化的分类。他们还提出了一种强大的颜色表示方法，通过检测并突出健康和患病眼睛中的角度依赖结构，有助于进一步解释D-OCT数据。

总之，实验结果显示，光感受器在各种视网膜疾病中混乱，证明了该方法的潜在医学意义。

原文出处：

Rossant， F.， K. Grieve， and M. Paques， Highlighting directional reflectance properties of retinal substructures from D-OCT images. IEEE Trans Biomed Eng， 2019

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-08-10 habb

    #OCT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2020-01-14 liao1632

    #定向#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-07-12 spoonycyy

    #Eng#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-06-04 zhaojie88

    #TRA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2020-01-31 sunylz

    #Bio#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-03-02 zutt

    #视网膜#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1858340, encodeId=268318583407e, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sat Aug 10 01:44:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769054, encodeId=21d21e6905439, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Tue Jan 14 08:44:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081536, encodeId=377e20815369e, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Fri Jul 12 08:44:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657135, encodeId=b4b1165e135ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 04 06:44:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918559, encodeId=8bd7191855908, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 31 01:44:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270178, encodeId=6cd012e0178c1, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609613, encodeId=772d1609613a5, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 02 13:44:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-03-02 ms3994565386320060

    #Med#

    0